From Research at med.fsu.edu Tue Dec 10 12:14:57 2019 From: Research at med.fsu.edu (Med Research) Date: Tue, 10 Dec 2019 17:14:57 +0000 Subject: Limited Submission Funding Opportunities Message-ID: <60E19361B71BE04F835C1FB3C18361BE01904589F4@FSUCOM128.med.ad.fsu.edu> The internal deadline for the Brain Research Foundation's Fay/Frank Seed Grant Program has passed, and therefore the first assistant or associate professor to claim FSU's spot will get this Limited Submission nomination. To claim the nomination and submit the letter of intent on January 7, go to https://www.research.fsu.edu/limitedsubmission/, locate the Brain Research Foundation entry, and then use the "contact OPD" email button (and please cc research at med.fsu.edu). The gist: This program supports new and innovative projects, especially those of junior faculty, who are working in new research directions. BRF Seed Grant awards are not intended to supplement existing grants. Each total grant is limited to $80,000 (direct costs) for a two-year grant period. Similarly, the internal deadline for the Macy Faculty Scholars Program has passed, and therefore the first medical school faculty member committed to a career in heath professional education to claim FSU's spot will get this Limited Submission nomination. To claim the nomination and submit an application on February 5, go to https://www.research.fsu.edu/limitedsubmission/, locate the Josiah Macy Jr. Foundation entry, and then use the "contact OPD" email button (and please cc research at med.fsu.edu). The gist: The Macy Faculty Scholars Program is designed to identify and nurture the careers of promising educational innovators in medicine and nursing. The program supports the Macy Faculty Scholars in leading new educational innovations at their home institutions and will provide opportunities for further career development through national meetings and participation in other Macy activities. $100k (plus fringe) per year for two years: 50% protected time to pursue a mentored educational project at the home institution. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Thu Dec 12 16:24:14 2019 From: Research at med.fsu.edu (Med Research) Date: Thu, 12 Dec 2019 21:24:14 +0000 Subject: Weekly Funding Opportunities Message-ID: <60E19361B71BE04F835C1FB3C18361BE0190458CEC@FSUCOM128.med.ad.fsu.edu> Whitehall Foundation Grant Programs: Basic Research in Neurobiology It is the Whitehall Foundation's policy to assist those dynamic areas of basic biological research that are not heavily supported by federal agencies or other foundations with specialized missions. The Whitehall Foundation is currently interested in basic research in neurobiology, defined as follows: Invertebrate and vertebrate (excluding clinical) neurobiology, specifically investigations of neural mechanisms involved in sensory, motor, and other complex functions of the whole organism as these relate to behavior. The overall goal should be to better understand behavioral output or brain mechanisms of behavior. The Whitehall Foundation does not support research focused primarily on disease(s) unless it will also provide insights into normal functioning. Research Grants Research grants are available to established scientists of all ages working at accredited institutions in the United States. Applications will be judged on the scientific merit and the innovative aspects of the proposal as well as on the competence of the applicant. Research grants of up to three years will be provided. A renewal grant with a maximum of two years is possible, but it will be awarded on a competitive basis. Research grants will not be awarded to investigators who have already received, or expect to receive, substantial support from other sources, even if it is for an unrelated purpose. Research grants normally range from $30,000 to $75,000 per year. Grants-in-Aid The Grants-in-Aid program is designed for researchers at the assistant professor level who experience difficulty in competing for research funds because they have not yet become firmly established. Grants-in-Aid can also be made to senior scientists. All applications will be judged on the scientific merit and innovative aspects of the proposal, as well as on past performance and evidence of the applicant?s continued productivity. Grants-in-Aid are awarded for a one-year period and do not exceed $30,000. Letter of intent due January 15, 2020; April 15, 2020; and October 1, 2020. Med-RA deadline to receive draft documents for January deadline: January 2, 2020. Michael J. Fox Foundation Invites Proposals for Ken Griffin Alpha-Synuclein Imaging Competition The Michael J. Fox Foundation (MJFF) has prioritized alpha-synuclein imaging as the approach most likely imaging to have an impact on therapeutic development. To that end, the foundation has issued a request for applications (RFA) for investigator-initiated studies designed to accelerate development of a selective alpha-synuclein PET tracer for use in clinical studies. The foundation encourages multidisciplinary teams to apply and id particularly interested in collaborations between academic and industry groups that have access to diverse compound libraries. Projects can include compound screening, tissue binding studies, lead identification and optimization, in vivo testing in appropriate models, and first-in-human testing of candidate tracers. Funding priority will be given to teams that show the greatest promise for delivering a selective tracer for human testing at the end of the funding period. Due January 17, 2020. Med-RA deadline to receive draft documents: January 6, 2020. Communication and Decision Making for Individuals with Inherited Cancer Syndromes (U01 Clinical Trial Optional) Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites the submission of applications requesting support for projects that will be conducted to develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve cancer risk communication between patients with an inherited susceptibility to cancer (and their families) and providers so that affected individuals can make informed clinical risk management decisions. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel/prevention-screening-working-group-report.pdf) Recommendation G (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel#ui-id-3 ): "Sponsor initiatives to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development and conduct implementation science research to accelerate development, testing, and broader adoption of proven strategies to significantly reduce cancer risk and address cancer health disparities in these areas." Projects that: (1) focus on delivery of culturally competent genetic counseling, especially with respect to members of underserved populations; or (2) test approaches to communicate uncertain genetic test results to individuals with an inherited susceptibility to cancer (and their families) and examine those individuals' behavioral, psychological, and clinical outcomes are considered high priority. Due January 21, 2020. Med-RA deadline to receive draft documents: January 7, 2020. Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 Clinical Trial Optional) This Funding Opportunity encourages multidisciplinary projects to investigate the potential health risks of environmental exposures of concern to a community and to implement an environmental public health action plan based on research findings. Projects supported under this program are expected to employ community-engaged research methods to not only conduct research but also to seamlessly translate research findings into public health action. This announcement reflects NIEHS goals in bi-directional communications and in supporting research to address environmental health disparities and environmental justice concerns. The Research to Action program is part of the National Institute of Environmental Health Sciences (NIEHS) ?Partnerships for Environmental Public Health? (PEPH) network (https://www.niehs.nih.gov/research/supported/translational/peph/index.cfm). Due January 21, 2020 and December 4, 2020. Med-RA deadline to receive draft documents for January deadline: January 7, 2020. Pfizer 2020 Rheumatology Competitive Grant Program Through the program, grants of up to $150,000 will be awarded in support of both clinical and basic science research on the pathogenesis and treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and/or ankylosing spondylarthrosis (AS), with a focus on projects that are most relevant to improving patient care. Investigators in the United States are encouraged to apply, including young investigators in the early stages of their career. Specific areas of interest include: * SpA ? Understanding the role of JAK-STAT signaling in the pathophysiology or disease progression of spondyloarthropathies (SpA) * understanding epidemiology of axSpA, including risk factors, spectrum/ progression from nr-axSpA to r-axSpA/AS * real-world evidence regarding efficacy and safety of tofacitinib in PsA as monotherapy vs. combination with csDMARDs * the efficacy and safety of tofacitinib in nr-axSpA and the long-term efficacy and safety of tofacitinib in PsA and r-axSpA * evidence for inhibition of structural progression (x-ray) and reduced inflammation (MRI, US) in r-axSpA and PsA * response in patient subtypes (e.g., oligo/polyarticular in PsA)/dominant SpA features (e.g., peripheral SpA, uveitis, enthesitis, dactylitis, IBD) * General (RA, PsA, axSpA) ? Unmet medical need/disease burden reasons for lack of/under treatment, treatment switch, patient satisfaction, and physical and psychosocial disease impact; understanding of the efficacy and safety of tofacitinib, specifically in patients with comorbid conditions; and approaches to improving management such as treating to target by monitoring response and adjusting therapy, evidence-based treatment algorithms, and factors predictive of response to therapy. Due January 27, 2020. Med-RA deadline to receive draft documents: January 13, 2020. Emotion Regulation, Aging and Mental Disorder (R21 / R01 Clinical Trial Not Allowed) R21 R01 These Funding Opportunity Announcements encourage applications for mechanistic research on age-related changes in emotion regulation and how they may contribute to mental disorders in middle-aged and older adults. In particular, research is sought that will advance understanding of irregularities in the integrative neural-behavioral mechanisms of emotion regulation in adult mood and anxiety disorders, and that will examine whether the irregularities are associated with typical or atypical maturational trajectories of emotion processing. Currently it is not known whether older adults who suffer episodes of affective dysregulation share the same patterns of improved emotional function with age as have been found to be typical of the older adult population in general. Research that helps to clarify whether they do or do not manifest typical emotion processing trajectories may lead to very different understandings of the irregularities involved in their dysregulation. It is anticipated that such studies may identify novel targets for mental health interventions or prevention efforts, or provide clues as to which available intervention strategies might be optimally applied to normalize emotion dysregulation or to strengthen emotional resilience at particular stages of the adult life cycle. Standard dates apply. Expires January 8, 2022. Med-RA deadline to receive draft documents for February 5 R01 deadline: January 23, 2020. Med-RA deadline to receive draft documents for February 16 R21 deadline: February 3, 2020. Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed) Several valuable and widely available data sets have been generated by multiple Common Fund programs. The purpose of this funding opportunity announcement (FOA) is to announce the availability of funding to demonstrate and enhance the utility of selected Common Fund data sets, including generating hypotheses and catalyzing discoveries. Award recipients are also asked to provide feedback on the utility of the Common Fund data resources. Due February 19, 2020. Med-RA deadline to receive draft documents: February 6, 2020. NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional) This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Due February 24, 2020; June 24, 2020; October 20, 2020; February 24, 2021; June 24, 2021; October 20, 2021; February 24, 2022; June 24, 2022; and October 20, 2022. Med-RA deadline to receive draft documents for February 2020 deadline: February 11, 2020. Assessing the Effects of Cannabinoids on HIV-Induced Inflammation (R01 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement is to encourage basic science and preclinical research to determine the biological mechanisms underlying the effects of cannabinoids and the endocannabinoid system on HIV-associated persistent inflammation and its consequent effects on nervous system function. Projects submitted in response to this FOA must include expertise and resources in both areas of HIV/AIDS and addiction science. Due March 11, 2020. Med-RA deadline to receive draft documents: February 27, 2020. Data Harmonization, Curation and Secondary Analysis of Existing Clinical Datasets (R61 / R33 Clinical Trial Not Allowed) This RFA invites applications from multidisciplinary teams to perform secondary data analysis, using existing datasets from two or more multi-site clinical research projects, including clinical trials, natural history studies, and/or comparative effectiveness research. Secondary analyses should address scientific and / or clinical hypotheses that can advance the understanding or care of neurological disorders and conditions within the NINDS mission. In this phased funding mechanism, applications are required to systematically and comprehensively perform cross-project data harmonization and curation, assessed using go/no-go data-quality metrics, prior to funding of the second phase of analyses. Consistent with the FAIR (findable, accessible, interoperable and reusable) data principles, this funding opportunity expects open-source cataloging of the processes and tools used for harmonization, curation, and analysis, as well as controlled access to the curated datasets. Due March 17, 2020. Med-RA deadline to receive draft documents: March 4, 2020. Impact of Alcohol on the Onset and Progression of Alzheimer?s Disease and Its Related Dementias (R01 ? Clinical Trial Optional) The goal of this FOA is to support basic and clinical research on the influence of alcohol on susceptibility and progression of Alzheimer's disease and its related dementias. Recent longitudinal studies have provided strong evidence that alcohol use disorder is associated with the high risk of all types of dementias, and frequent heavy drinking increases risk of both Alzheimer's disease and vascular dementia. Even moderate alcohol consumption may be a risk factor for adverse brain outcomes and cognitive decline. Although these studies link heavy and frequent alcohol drinking to dementias in aging populations, mechanisms contributing to this relationship are not well understood. With this FOA, we solicit research projects that combine diverse expertise and use innovative approaches to investigate mechanisms by which alcohol affects brain aging processes to produce dementias and influences development of Alzheimer's disease. This FOA strongly encourages collaborations between alcohol researchers and experts in Alzheimer's disease and its related dementia research. Due March 24, 2020. Med-RA deadline to receive draft documents: March 11, 2020. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Thu Dec 19 09:42:24 2019 From: Research at med.fsu.edu (Med Research) Date: Thu, 19 Dec 2019 14:42:24 +0000 Subject: Limited Submission first-come first-nominated: Mary Kay Foundation Cancer Research Grant In-Reply-To: <72BE99F1-7461-4ED8-BED2-70904699C8C1@med.fsu.edu> References: <72BE99F1-7461-4ED8-BED2-70904699C8C1@med.fsu.edu> Message-ID: The internal deadline for the Mary Kay Foundation Cancer Research Grant Competition has passed, and therefore the first assistant, associate, or full professor to claim FSU?s spot will get this Limited Submission nomination. To claim the nomination and submit the application on February 7, go to https://www.research.fsu.edu/limitedsubmission/, locate the Mary Kay Foundation entry, and then use the ?contact OPD? email button (and please cc research at med.fsu.edu). The RFP and application instructions are attached. In brief: The Mary Kay Foundation funds innovative translational research in ovarian, uterine, breast, and cervical cancer. The program will fund projects up to $100,000 (combined direct and indirect costs; indirect costs cannot exceed 15%). Funds may be used in a one-year period or up to two years. -------------- next part -------------- An HTML attachment was scrubbed... URL: -------------- next part -------------- A non-text attachment was scrubbed... Name: 2020_TMKF RFP.docx Type: application/vnd.openxmlformats-officedocument.wordprocessingml.document Size: 15880 bytes Desc: 2020_TMKF RFP.docx URL: -------------- next part -------------- A non-text attachment was scrubbed... Name: 2019_TMKF_Cancer Grant Applicant_UserGuide.pdf Type: application/pdf Size: 573888 bytes Desc: 2019_TMKF_Cancer Grant Applicant_UserGuide.pdf URL: